XML 37 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMON STOCK AND STOCK-BASED COMPENSATION PLANS (Tables)
3 Months Ended
Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Stock Option Activity

A summary of the Company’s stock option and SARs activities and related information for the three months ended March 31, 2018, are as follows:

 

     Number of
options
and SAR
units (1)
    Weighted
average
exercise
price
     Weighted
average
remaining
contractual
term
    
Aggregate
intrinsic-
value
 

Outstanding as of December 31, 2017

     729,017     $ 19.77        5.2      $ 19,229  

Granted

     —         —          

Exercised

     (6,392     15.94        

Forfeited or expired

     (1,044     18.51        
  

 

 

   

 

 

       

Outstanding as of March 31, 2018 (2)

     721,581     $ 19.81        5.0      $ 11,828  
  

 

 

   

 

 

    

 

 

    

 

 

 

Exercisable as of March 31, 2018 (3)

     527,310     $ 19.01        4.4      $ 9,065  
  

 

 

   

 

 

    

 

 

    

 

 

 

 

(1) The SAR units are convertible for a maximum number of shares of the Company’s common stock equal to 75% of the SAR units subject to the grant.
(2) Due to the ceiling imposed on the SAR grants, the outstanding amount equals a maximum of 656,498 shares of the Company’s common stock issuable upon exercise.
(3) Due to the ceiling imposed on the SAR grants, the exercisable amount equals a maximum of 475,608 shares of the Company’s common stock issuable upon exercise.
Summary of Restricted Stock Units Activity

A summary of the Company’s RSU activities and related information for the three months ended March 31, 2018, are as follows:

 

     Number of
RSUs
     Weighted Average
Grant-Date
Fair Value
 

Unvested as of December 31, 2017

     560,616      $ 29.31  

Granted

     230,000        36.05  

Vested

     (153,503      25.92  

Forfeited or expired

     (4,001      34.10  
  

 

 

    

 

 

 

Unvested as of March 31, 2018

     633,112      $ 32.55  
  

 

 

    

 

 

 
Equity-Based Compensation Expense Included in Interim Condensed Consolidated Statements of Income

The following table shows the total equity-based compensation expense included in the interim condensed consolidated statements of income:

 

     Three months ended
March 31,
 
     2018
(unaudited)
     2017
(unaudited)
 

Cost of revenue

   $ 157      $ 91  

Research and development, net

     1,269        871  

Sales and marketing

     454        289  

General and administrative

     891        698  
  

 

 

    

 

 

 

Total equity-based compensation expense

   $ 2,771      $ 1,949  
  

 

 

    

 

 

 
Assumptions Used to Estimate Fair Value of Employee Stock Purchase Plan

The fair value for rights to purchase shares of common stock under the Company’s employee stock purchase plan was estimated on the date of grant using the following assumptions:

 

     Three months ended
March 31,
 
     2018
(unaudited)
     2017
(unaudited)
 

Expected dividend yield

     0%        0%  

Expected volatility

     35%-42%        35%-46%  

Risk-free interest rate

     0.7%-1.6%        0.5%-0.7%  

Contractual term of up to

     24 months        24 months